SG/CALL/EVOTEC/31/0.1/20.09.24 Share Price

Warrant

DE000SV7GVU8

Delayed Deutsche Boerse AG 08:16:00 29/05/2024 pm IST
0.001 EUR 0.00% Intraday chart for SG/CALL/EVOTEC/31/0.1/20.09.24
6 months-97.78%
Current year-99.09%
Date Price Change
29/24/29 0.001 0.00%
28/24/28 0.001 0.00%
27/24/27 0.001 0.00%
24/24/24 0.001 0.00%
23/24/23 0.001 0.00%

Delayed Quote Deutsche Boerse AG

Last update May 29, 2024 at 08:16 pm IST

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying EVOTEC SE
IssuerLogo Issuer Société Générale Société Générale
WKN SV7GVU
ISINDE000SV7GVU8
Date issued 14/06/2023
Strike 31
Maturity 20/09/2024 (114 Days)
Parity 10 : 1
Emission price 0.24
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.25
Lowest since issue 0.001

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Sector
-
More about the company

Ratings for Evotec SE

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Evotec SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
9.035 EUR
Average target price
20.79 EUR
Spread / Average Target
+130.11%
Consensus